Schrag D - Search Results

1

Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation.

Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Saltz LB, Goodman KA, Minsky BD, Wong WD, Weiser MR. Quah HM, et al. Among authors: schrag d. Cancer. 2008 Jul 1;113(1):57-64. doi: 10.1002/cncr.23516. Cancer. 2008. PMID: 18442099 Free article.

2

Age and adjuvant chemotherapy use after surgery for stage III colon cancer.

Schrag D, Cramer LD, Bach PB, Begg CB. Schrag D, et al. J Natl Cancer Inst. 2001 Jun 6;93(11):850-7. doi: 10.1093/jnci/93.11.850. J Natl Cancer Inst. 2001. PMID: 11390534

3

Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results--Medicare.

Schrag D, Gelfand SE, Bach PB, Guillem J, Minsky BD, Begg CB. Schrag D, et al. J Clin Oncol. 2001 Sep 1;19(17):3712-8. doi: 10.1200/JCO.2001.19.17.3712. J Clin Oncol. 2001. PMID: 11533092

4

Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer.

Schrag D, Rifas-Shiman S, Saltz L, Bach PB, Begg CB. Schrag D, et al. J Clin Oncol. 2002 Oct 1;20(19):3999-4005. doi: 10.1200/JCO.2002.11.084. J Clin Oncol. 2002. PMID: 12351597

5

Adherence to surveillance among patients with superficial bladder cancer.

Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB. Schrag D, et al. J Natl Cancer Inst. 2003 Apr 16;95(8):588-97. doi: 10.1093/jnci/95.8.588. J Natl Cancer Inst. 2003. PMID: 12697851

6

Use of information resources by patients with cancer and their companions.

Basch EM, Thaler HT, Shi W, Yakren S, Schrag D. Basch EM, et al. Among authors: schrag d. Cancer. 2004 Jun 1;100(11):2476-83. doi: 10.1002/cncr.20261. Cancer. 2004. PMID: 15160355 Free article.

7

Use of surgery among elderly patients with stage IV colorectal cancer.

Temple LK, Hsieh L, Wong WD, Saltz L, Schrag D. Temple LK, et al. Among authors: schrag d. J Clin Oncol. 2004 Sep 1;22(17):3475-84. doi: 10.1200/JCO.2004.10.218. J Clin Oncol. 2004. PMID: 15337795

8

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB. Chung KY, et al. Among authors: schrag d. J Clin Oncol. 2005 Mar 20;23(9):1803-10. doi: 10.1200/JCO.2005.08.037. Epub 2005 Jan 27. J Clin Oncol. 2005. PMID: 15677699

9

An increasingly common challenge: management of the complete responder with multi-focal metastatic colorectal cancer.

Schrag D, Weiser M, Schattner M, Shia J, Akhurst T. Schrag D, et al. J Clin Oncol. 2005 Mar 20;23(9):1799-802. doi: 10.1200/JCO.2005.02.185. J Clin Oncol. 2005. PMID: 15774773 No abstract available.

10

The development of a validated instrument to evaluate bowel function after sphincter-preserving surgery for rectal cancer.

Temple LK, Bacik J, Savatta SG, Gottesman L, Paty PB, Weiser MR, Guillem JG, Minsky BD, Kalman M, Thaler HT, Schrag D, Wong WD. Temple LK, et al. Among authors: schrag d. Dis Colon Rectum. 2005 Jul;48(7):1353-65. doi: 10.1007/s10350-004-0942-z. Dis Colon Rectum. 2005. PMID: 15868235

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

456 results

Search Page

Filters